Standout Papers

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cel... 2018 2026 2020 2023 444
  1. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018)
    Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 69 standout
Sub-graph 1 of 21

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
1 intermediate paper

Works of Anne Sumbul being referenced

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
2019

Author Peers

Author Last Decade Papers Cites
Anne Sumbul 728 834 369 17 1.0k
Charles Foussard 864 588 256 21 1.0k
Margaretha G.M. Roemer 541 680 380 18 937
P Solal-Céligny 1046 735 215 13 1.3k
Junichi Kiyasu 775 725 430 40 1.2k
BN Nathwani 956 748 141 22 1.1k
Hans‐Heinrich Wacker 775 536 497 26 1.3k
H K Müller‐Hermelink 676 488 252 30 1.2k
Courtney Connelly 503 663 398 13 878
Rie Hyo 954 754 347 27 1.2k
Maike Nickelsen 1072 674 314 40 1.2k

All Works

Loading papers...

Rankless by CCL
2026